Exclusion of suspect data raises question mark over safety of common plasma substituteBMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f1132 (Published 19 February 2013) Cite this as: BMJ 2013;346:f1132
- Susan Mayor
Hydroxyethyl starch, a commonly used plasma substitute, is associated with increased risk of death and acute kidney injury in critically ill patients needing an increase in blood fluid volume, according to a new meta-analysis1 that excluded trials from an investigator some of whose research has been retracted because of scientific misconduct.
“This study highlights the serious implications of scientific misconduct on patient safety,” warned Massimo Antonelli, professor of intensive care medicine at the Università Cattolica del Sacro Cuore, Rome, Italy, in an accompanying editorial.2 He added that it illustrated the importance of updating guidelines regularly as the evidence base changes.
Synthetic colloids such as hydroxyethyl starch were approved in the 1960s without …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial